Core Insights - Coppernico Metals Inc. has reported positive assay results from its Phase 1 drill program at the Sombrero Project in Peru, confirming broad intervals of copper-gold mineralization and supporting the geological model [1][6][9] - The company is currently seeking expanded permits to access priority targets as drilling is temporarily paused [1][15] Phase 1 Drill Program Highlights - The Phase 1 drill program included 8,232.9 meters of diamond drilling across 20 holes, targeting geophysical and geochemical anomalies [1][3] - Results indicate continuity of copper-gold mineralization across multiple zones, particularly at the Ccascabamba target area [3][9] - Notable intercepts include 9.85 meters at 0.26% copper and 0.46 g/t gold, and 21.85 meters at 0.22% copper [5][10] Geological Insights - The drilling has revealed a complex network of causative intrusions, particularly around the Hojota area, indicating a robust skarn alteration system exceeding 300 meters in width [5][9] - Mineralization is influenced by proximity to intrusions, favorable host lithologies, and structural complexities [5][7] - Geological indicators suggest the potential for significant extensions of the mineralized system beyond the current permit boundaries [6][9] Regional Exploration and Target Pipeline - The company is expanding its pipeline of exploration targets through ongoing mapping and sampling programs beyond the Ccascabamba area [4][11] - New targets identified include the Nioc target area and the Antapampa target, which may represent extensions of existing systems or new discoveries [13][14] - The company is actively advancing permitting efforts to access high-priority targets located beyond current drill permit boundaries [15] Future Plans - The company aims to secure key permits to facilitate drilling in high-grade skarn and porphyry targets in the next phase [6][15] - Additional updates on exploration results and permit advancements are expected in the coming months [4][11]

Core Viewpoint - Kornit Digital Ltd. reported its first quarter results for 2025, highlighting its commitment to sustainable, on-demand digital fashion and textile production technologies amidst a challenging macro environment [2][3]. Financial Performance - First quarter revenues reached $46.5 million, an increase from $43.8 million in the same period last year [7]. - The GAAP gross profit margin improved to 42.6% from 32.3% year-over-year, while the non-GAAP gross profit margin rose to 45.2% from 37.5% [7]. - The company reported a GAAP net loss of $5.1 million, or $0.11 per basic share, compared to a net loss of $13.2 million, or $0.28 per basic share, in Q1 2024 [7][21]. - Non-GAAP net income for the first quarter was $0.6 million, or $0.01 per diluted share, compared to a non-GAAP net loss of $5.3 million, or $0.11 per basic share, in the prior year [7][21]. - Adjusted EBITDA loss was $3.9 million, an improvement from a loss of $7.8 million in Q1 2024, with an adjusted EBITDA margin of negative 8.4% compared to negative 17.9% [7][30]. Business Model and Market Opportunity - Kornit’s Apollo platform, combined with its AIC model, is driving significant growth in impressions and unlocking a mass production segment estimated at 4.5 billion impressions [2]. - The company reported annual recurring revenue from AIC contracts of $14.5 million, indicating strong initial adoption of this new business model [6]. Guidance - For the second quarter of 2025, Kornit expects revenues to be between $49 million and $55 million, with an adjusted EBITDA margin projected between negative 4% and 4% [4].

Core Viewpoint - Nvidia has shown a significant rebound in its stock price, rising 17.36% in May and trading at $129.93 as of May 14, with expectations of further increases towards $150 by June 1, 2025 [1][8]. Group 1: Stock Performance and Predictions - Nvidia's stock has rebounded sharply since dipping below $100 in mid-April, with a current price of $129.93 [1]. - The AI predicts that Nvidia shares will likely reach $138 by June 1, 2025, supported by recent positive developments [8][9]. - The stock has broken through its 200-day moving average, indicating a bullish trend [5]. Group 2: Market Dynamics and Technical Analysis - Recent developments include bullish agreements with international partners and a partnership with the Saudi state-backed startup Humain [5]. - The 90-day trade truce between the U.S. and China has alleviated selling pressure, shifting investor sentiment towards optimism [9]. - Resistance levels for Nvidia stock are identified at $130 and $150, with support zones at $115 and $96 [6]. Group 3: Analyst Sentiment - UBS has given Nvidia a bullish 'buy' rating while downgrading the 12-month price target from $180 to $175, reflecting cautious optimism [11]. - Bernstein reaffirmed its positive outlook for Nvidia shares, maintaining a $180 price target [13].

Core Insights - The U.S. FDA has accepted the Biologics License Application (BLA) for RGX-121, a gene therapy for Mucopolysaccharidosis II (MPS II), with a target action date of November 9, 2025 [1][5] - NS Pharma will exclusively commercialize RGX-121 in the U.S. upon potential approval, following a strategic partnership with REGENXBIO [2][3] Company Overview - NS Pharma, a subsidiary of Nippon Shinyaku Co., Ltd., focuses on developing and commercializing innovative therapies [8] - REGENXBIO is a clinical-stage biotechnology company specializing in gene therapy, particularly AAV Therapeutics [7] Product Details - RGX-121 is designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system, potentially providing a long-term solution for MPS II [4] - The therapy has received multiple FDA designations, including Orphan Drug Product and Rare Pediatric Disease [5] Disease Context - MPS II, also known as Hunter Syndrome, is a rare genetic disorder caused by a deficiency in the I2S enzyme, leading to significant health challenges, particularly neurological [6]

Core Points - The Pet Valu Walk for Dog Guides will take place on May 25, 2025, in 200 communities across Canada, aiming to raise $1.6 million for providing dog guides to Canadians with disabilities at no cost [3][4] - The event marks the 40th anniversary of the Walk, which started as a small community event and has grown significantly, now supporting seven different programs with over 800 working dog guides [4][5] - Each dog guide costs approximately $35,000 to breed, raise, train, and place, highlighting the financial need for fundraising events like the Pet Valu Walk [4] Company Overview - Pet Valu is Canada's leading retailer of pet food and supplies, with over 800 locations and a strong commitment to community involvement through sponsorship and participation in events like the Pet Valu Walk [8] - The company has been a national sponsor of the Walk since 2017 and has contributed significantly to the Dog Guides organization, including financial support for over 220 dog guide teams [6][8] - Pet Valu is also investing in a new $50 million training facility to enhance its support for Dog Guides and increase the number of teams graduated annually [5][6] Industry Impact - The Lions Foundation of Canada Dog Guides provides essential services to Canadians with disabilities, empowering them to live independently by offering dog guides at no cost [9] - The organization has evolved over the past four decades, expanding its programs and increasing its operational capacity, which is supported by community fundraising events like the Pet Valu Walk [4][5] - The collaboration between Pet Valu and Dog Guides exemplifies the positive impact of corporate sponsorship in the non-profit sector, enhancing the quality of life for individuals with disabilities [7][9]

(All amounts in release are in Canadian dollars) OTTAWA, Ontario, May 14, 2025 (GLOBE NEWSWIRE) -- Calian® Group Ltd. (TSX:CGY), a mission critical solutions company, with a focus on defence, space, healthcare and strategic growth markets, today released its results for the second quarter ended March 31, 2025. “Our consolidated second quarter results reflect momentum in some areas, whilst challenging headwinds in others,” said Kevin Ford, Calian CEO. “Our defence solutions in both North America and Europe g ...

Core Viewpoint - Milestone Pharmaceuticals is actively addressing the Chemistry, Manufacturing, and Controls (CMC) issues raised by the FDA regarding its lead product CARDAMYST for the treatment of paroxysmal supraventricular tachycardia (PSVT) and is preparing for a Type A meeting with the FDA to resolve these issues [1][2][6]. Financial Results - As of March 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $56.0 million, a decrease from $69.7 million as of December 31, 2024 [11]. - The company reported no revenue for the first quarter of 2025, consistent with the same period in 2024 [11]. - Research and development expenses increased to $5.0 million in Q1 2025 from $3.6 million in Q1 2024, primarily due to higher consulting costs [11]. - General and administrative expenses rose to $5.2 million in Q1 2025 from $4.0 million in the prior year, driven by increased outside service costs [11]. - Commercial expenses surged to $10.4 million in Q1 2025 from $2.9 million in Q1 2024, reflecting preparations for the launch of CARDAMYST [11]. - The net loss for the first quarter of 2025 was $20.8 million, compared to a net loss of $10.4 million in the same period last year [11]. Product Development and Regulatory Updates - The FDA issued a Complete Response Letter (CRL) for CARDAMYST in March 2025, citing two key CMC issues: the need for additional information on nitrosamine impurities and a new facility inspection to ensure compliance with Good Manufacturing Practices (GMP) [6]. - The Phase 3 study protocol for etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) has been finalized, but enrollment is paused to focus on resolving the CRL for PSVT [4]. - A new method of use patent for etripamil nasal spray was issued, potentially extending intellectual property protection until July 2042 [6]. - CARDAMYST was recognized in an independent survey as a new drug expected to significantly impact patient health, with 40% of respondents selecting it [6]. Company Overview - Milestone Pharmaceuticals is focused on developing innovative cardiovascular solutions, with etripamil as its lead investigational product designed for self-administration in treating symptomatic episodes of PSVT and AFib-RVR [9][8].

ON TodayONONON$57.41 +6.10 (+11.89%) 52-Week Range$33.55▼$64.05P/E Ratio133.51Price Target$58.18Add to WatchlistON Holdings' NYSE: ONON stock price surged following the Q1 earnings release and 2025 update, leading its and other high-end retail stocks into technical price reversals. The results are favorable for itself, distinguishing it as a leading footwear, athletic, and apparel brand, and indicate strength in a category that includes names like Lululemon NASDAQ: LULU, a more direct competitor, and Willi ...

Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip stocks, BDC's, and REITs. I am a buy-and-hold investor who prefers quality over quantity and plans to supplement his retirement income ...

QUEBEC CITY, Canada, May 14, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an AI-powered software company recognized for its innovation in advanced driver assistance systems (ADAS) and autonomous driving (AD), is pleased to announce the launch of LeddarSim™, a next-generation simulation platform purposely built to reduce the gap between virtual testing and real-world deployment. LeddarSim redefines the standards of ADAS and AD development by closing the long-standing simu ...